ERK
ERK é uma proteína chave na via de sinalização MAPK (Mitogen-Activated Protein Kinase), que está envolvida na transmissão de sinais dos receptores de superfície celular para o DNA no núcleo da célula. ERK desempenha um papel crucial na regulação de vários processos celulares, incluindo proliferação, diferenciação e sobrevivência. A desregulação da sinalização ERK está associada ao desenvolvimento de câncer e outras doenças, tornando-a um alvo importante para intervenções terapêuticas. Na CymitQuimica, oferecemos uma seleção de inibidores e moduladores de ERK de alta qualidade para apoiar sua pesquisa em sinalização celular, oncologia e desenvolvimento terapêutico.
Foram encontrados 204 produtos de "ERK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CXJ-2
CAS:CXJ-2, a cyclic peptide, binds EDPs, inhibits PI3K/ERK, and reduces hepatic cell growth/migration, offering antifibrotic effects.Fórmula:C55H87N15O22Pureza:98%Cor e Forma:SolidPeso molecular:1310.37SKI2496
CAS:SKI2496: potent, oral GnRH receptor antagonist, hGnRHR IC50=0.46nM, 84% LH inhibition at 12h, 76% at 24h, selective for humans over monkeys/rats.Fórmula:C35H36F7N5O5Cor e Forma:SolidPeso molecular:739.68ERK1/2 inhibitor 7
CAS:ERK1/2 inhibitor 7 is a potent inhibitor of ERK, acting on ERK2 (IC50: 0.94 nM).Fórmula:C23H22FN7OSCor e Forma:SolidPeso molecular:463.53EVT801
CAS:EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces CCL4, CCL5 and MDSC.Fórmula:C19H21N5O3Pureza:97.4%Cor e Forma:SolidPeso molecular:367.4MK-8353
CAS:MK-8353 (SCH900353) is a potent, selective and orally available inhibitor of ERK1/2 (IC50s of 23.0 nM and 8.8 nM, respectively)Fórmula:C37H41N9O3SPureza:96.15% - 97.19%Cor e Forma:SolidPeso molecular:691.84ERK2 IN-1
CAS:<p>ERK2 IN-1 is a selective ERK2 inhibitor with an IC50 of 7 nM.</p>Fórmula:C36H34FN7O2SPureza:98%Cor e Forma:SolidPeso molecular:647.76MAP855
CAS:MAP855: potent, selective, oral MEK1/2 inhibitor; IC50=3 nM, pERKEC50=5 nM; effective on wild-type/mutant MEK1/2.Fórmula:C28H23ClF2N6O3Cor e Forma:SolidPeso molecular:564.97SHR2415
SHR2415: Potent, selective ERK1/2 inhibitor, oral; ERK1 IC50: 2.8 nM, ERK2 IC50: 5.9 nM; effective in Colo205 (IC50: 44.6 nM), for cancer research.Fórmula:C23H22ClN7O2Cor e Forma:SolidPeso molecular:463.92Hypothemycin
CAS:Hypothemycin, a fungal polyketide, inhibits multiple kinases (VEGFR, MEK, FLT-3, PDGFR, ERK) with Kis ranging from 10 nM to 2.4 μM.Fórmula:C19H22O8Pureza:98%Cor e Forma:SolidPeso molecular:378.37ATX inhibitor 26
CAS:ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. It effectively inhibits cell migration and collagen gel contraction. Additionally, ATX inhibitor 26 demonstrates significant antifibrotic activity, reducing collagen deposition in a Bleomycin (BLM)-induced pulmonary fibrosis model.Fórmula:C18H19Cl2N7O3Cor e Forma:SolidPeso molecular:452.30ERK1/2 inhibitor 6
CAS:ERK1/2 inhibitor 6 - potent cancer/inflammation treatment from WO2021063335A1.Fórmula:C27H29ClFN7O5Cor e Forma:SolidPeso molecular:586.01KRASG12C IN-15
CAS:KRASG12C IN-15 (Compound 21) is an orally active KRASG12C inhibitor that effectively blocks SOS1-mediated GDP/GTP exchange with an IC50 of 19 nM. It inhibits ERK phosphorylation with an IC50 of 0.051 μM and reduces the viability of KRASG12C mutant MIA PaCa-2 cells with an IC50 of 0.023 μM. Additionally, KRASG12C IN-15 demonstrates antitumor activity in a MIA PaCa-2 xenograft mouse model.Fórmula:C31H32FN3O2Cor e Forma:SolidPeso molecular:497.603DOR agonist 2
CAS:Compound 3 (DOR agonist 2) acts as a Delta Opioid Receptor agonist. It inhibits the expression of TNF-α, obstructs NF-κB transportation to the nucleus, and activates the G protein-mediated ERK1/2 pathway. This compound is useful for research into neurodegenerative diseases.Fórmula:C29H26N2O3Cor e Forma:SolidPeso molecular:450.53SOS1 activator 2
CAS:<p>SOS1 activator 2 (Compound 65) is a benzothiazole derivative and an activator of SOS1. It demonstrates a high binding affinity for SOS1, with a Kd of 9 nM. By modulating the Ras-ERK signaling pathway, SOS1 activator 2 is suitable for tumor research.</p>Fórmula:C26H28ClFN6Cor e Forma:SolidPeso molecular:478.992(rel)-AR234960
CAS:(rel)-AR234960 is an active relative configuration of AR234960. AR234960 is a non-peptide agonist of MAS.Fórmula:C27H30FN5O5SCor e Forma:SolidPeso molecular:555.63ERK-IN-2
CAS:ERK-IN-2, an ERK2 inhibitor, exhibits an IC50 value of 1.8 nM. At doses greater than 10 μM, it may induce off-target toxicity and/or activity [1].Fórmula:C16H18ClN5O2Pureza:98%Cor e Forma:SolidPeso molecular:347.80KU004
CAS:<p>KU004, a potent dual EGFR/HER2 inhibitor, exhibits anticancer properties. It inhibits the proliferation of human breast cancer SKBR3 cells by inducing G1 phase arrest. KU004 blocks the activation of HER2, EGFR, and the downstream Akt and Erk pathways, primarily inducing apoptosis (Apoptosis) through the extrinsic pathway. Additionally, KU004 is a novel quinazoline derivative.</p>Fórmula:C29H27ClFN4O2PCor e Forma:SolidPeso molecular:548.98KRAS inhibitor-27
CAS:<p>KRAS inhibitor-27 (Compound 15h) is a KRAS inhibitor that effectively targets KRAS G12D/G12V mutated cells (AsPC-1 and SW620) and wild-type KRAS cells (HT-29), with IC50 values of 378 nM, 0.6 nM, and 3230 nM, respectively. It reduces ERK phosphorylation, with IC50 values of 0.6 nM and 1 nM in AsPC-1 and SW620 cells, respectively, and decreases DUSP4 expression, thereby inhibiting the MAPK signaling pathway.</p>Fórmula:C31H28ClF3N6O3SCor e Forma:SolidPeso molecular:657.106AL 8810
CAS:AL-8810 is an 11β-fluoro analog of PGF 2α with selective antagonist effects at the PGF 2α receptor (FP receptor) [1].Fórmula:C24H31FO4Cor e Forma:SolidPeso molecular:402.5Rineterkib
CAS:Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.Fórmula:C26H27BrF3N5O2Pureza:99.73%Cor e Forma:SolidPeso molecular:578.42
